InvestorsHub Logo
Followers 91
Posts 11376
Boards Moderated 0
Alias Born 06/06/2014

Re: Doc328 post# 464330

Wednesday, 07/17/2024 9:03:44 AM

Wednesday, July 17, 2024 9:03:44 AM

Post# of 464660
Their larger AD clinical program not withstanding, it was hard to justify Cassava's much higher market cap. Yes, if their phase 3's don't show credible AD efficacy signal, the company is in deep trouble; there are now legit questions around their lead molecule's MOA.

Look at the pains they take to emphasize that 3rd parties are handling the trial data and analysis.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News